$18.48B in CY2024 Part D spend17.9M claims · 5.0M beneficiaries · 329 plans surveyed
Questions a plan sponsor actually asks.
What is Empagliflozin used for?
SYNJARDY SYNJARDY is a combination of empagliflozin, a sodium-glucose co-transporter 2 (SGLT2) inhibitor and metformin hydrochloride (HCl) immediate-release, a biguanide, indicated as an adjunct to....
Is there a generic for Empagliflozin?
No. Empagliflozin is brand-only with no generic equivalents currently in market.
How much does my plan pay for Empagliflozin?
Across 329 Part D plans, Empagliflozin averages $11.20/unit (NADAC). Lowest available: $11.20/unit. Highest in distribution: $11.20/unit.
Is Empagliflozin on the FDA shortage list?
No. Empagliflozin is not currently on the FDA Drug Shortage Database.
8 additional drug-specific questions are indexed in the page's FAQPage schema for search engines and LLM crawlers, beyond what renders visually above. View page source for the complete JSON-LD.
Same class. Different math.
Sources · every number above traces back.
Drug identity, dosage forms, brand names: openFDA NDC Directory · First approval, ANDA history: FDA Orange Book (2 approvals on file) · NADAC unit costs: CMS NADAC weekly file (6 NDCs benchmarked) · Formulary tier and PA placement: CMS Part D Formulary file (329 plans) · Annualized spend, claims, beneficiaries: CMS Part D Spending Dashboard (CY2024) · Shortage status: FDA Drug Shortage Database · 340B exposure: HRSA OPAIS. Methodology and reproducibility notes on /methodology.